MATERIAL SAFETY DATA SHEET
Moexipril 7.5 mg Tablets
Paddock Laboratories, Inc. Emergency Assistance:
CHEMTREC庐 (24-hour)
3940 Quebec Avenue North 1-800-424-9300
Minneapolis, MN 55427
Tel: (763) 546-4676 Paddock Technical Assistance: 1-800-328-5113
Creation Date: 23 August 2004 Revision Date: 23 August 2004
SECTION 1: PRODUCT IDENTIFICATION
PRODUCT NAME: Moexipril 7.5 mg Tablets
COMMON NAME: Moexipril 7.5 mg Tablets
CHEMICAL NAME: Moexipril HCl
SYNONYMS: NA
CHEMICAL FORMULA: C27H34N2O7HCl
CHEMICAL FAMILY: ACE Inhibitor, Antihypertensive
SECTION 2: COMPOSITION AND INGREDIENTS
CHEMICAL NAME CAS# % w/w OSHA PEL ACGIH TLV IDLH
Moexipril HCl 82586-52-5 <10 NE NE NE
Magnesium Oxide, USP 01309-48-4 <10 15 mg/m 3 10 mg/m 3 NE
Lactose Monohydrate, NF 64044-51-5 >50 NE NE NE
Povidone K-29 9003-39-8 <10 NE NE NE
Crospovidone XL, NF 9003-39-8 <10 NE NE NE
Colloidal Silicon Dioxide, NF 112945-52-5 <10 6 mg/m3 10 mg/m3 NE
(Aerosil 200)
Magnesium Stearate, NF 00557-04-0 <10 15 mg/m 3 10 mg/m3 NE
Opadry Mixture <10 10 mg/m3 5 mg/m 3 NE
NE = Not Established, Specific amounts are considered proprietary information.
SECTION 3: HAZARDS INDENTIFICATION
EMERGENCY OVERVIEW: Moexipril 7.5 mg tablets are light beige, round, biconvex, film coated tablets with 鈥?110鈥?
debossing on one side and scored on the other side of the tablet. The ingredients listed are non-hazardous.
Symptoms of Overexposure by Route of Exposure: Overexposure by ingestion includes cough, diarrhea, and
flushing, rash, and muscle pain. Some individuals may experience swelling of the face, extremities, lips, tongue,
glottis, and/or larynx. Swelling of the tongue or larynx may result in difficult breathing. Overdosage results primarily
in hypotension which could lead to dizziness, lightheadedness, and fainting.
TO THE BEST OF OUR KNOWLEDGE THE INFORMATION CONTAINED HEREIN IS ACCURATE AS OF THE DATE HEREOF.
ANY DETERMINATION AS TO THE SUITABILITY OF THE PRODUCT FOR ANY PARTICULAR PURPOSE, ITS SAFE USE OR
DISPOSAL SHALL BE THE RESPONSIBILITY OF THE USER. THE INFORMATION CONTAINED HEREIN IS IN NO WAY
INTENDED TO SUPPLEMENT, MODIFY OR SUPERSEDE THE INFORMATION PROVIDED IN THE PRODUCT PACKAGE
INSERT WITH RESPECT TO THE USE OF THE PRODUCT FOR MEDICAL PURPOSES.
MSDS 鈥? Moexipril HCl 7.5mg Tablets Page 2 of 6
Inhalation: Inhalation is not likely to occur, however avoid breathing or creating dust. If symptoms occur, move to
fresh air and seek medical attention.
Contact with Skin or Eyes: Contact with eyes is not likely to occur, however avoid creating dust. Incase of contact
with eyes wash thoroughly with water for at least 15 minutes and consult a physician if irritation persists. There is no
hazards associated with contact with skin, however if irritation occurs, wash thoroughly with soap and water and seek
medical attention.
Ingestion: Accidental ingestion of normal dosages (no more than 4 tablets in 24 hours for adults) is not likely of
cause significant adverse health effects.
Health Effects or Risks From Exposure (An explanation in lay terms):
Acute: Not Known
Chronic: Not Known
Medical Conditions Aggravated by Over Exposure: Congestive heart failure, ischemic heart disease (low blood
supply to the heart), aortic stenosis (narrow aortic valve which causes decreased heart function, characterized by
faint pulse in hands and feet, exercise intolerance, and/or chest pain), and cerebrovascular disease (disease of the
blood vessels of the brain.)
Other Comments: When using Moexipril during the second and third trimesters of pregnancy, ACE inhibitors can
cause injury and even death to the developing fetus.
Pre-Existing Medical Conditions: Not Known
SECTION 4: FIRST AID MEASURES
Skin Exposure: Thoroughly wash with mild soap and water if irritation develops.
Eye Exposure: Immediately flush eye with copious amounts of water and seek medical attention.
Inhalation: Inhalation exposure is not expected to occur. If symptoms occur, move to fresh air and seek
medical attention.
Ingestion: In the case of exposure to excessive levels of dust, remove to fresh air. Get medical
attention if cough or other symptoms develop.
NOTE TO PHYSICIANS: Although rare, some individuals may experience significant edema of the face, tongue,
glottis, or larynx when treated with ACE inhibitors. Appropriate treatment should be administered promptly.
SECTION 5: FIRE / EXPLOSION HAZARDS & FIRE-FIGHTING MEASURES
Flash Point: NE Autoignition Temperature: NE
Flammable Limits (in air by volume, %): Lower: NE Upper: NE
Fire Extinguishing Equipment: Use extinguishing agent suitable for type of surrounding fire.
Water Spray: OK Carbon Dioxide: OK Halon: OK
Foam: OK Dry Chemical: OK Other: Any 鈥淎BC鈥? Class
Unusual Fire and Explosion Hazards: No unusual fire or explosion hazards are expected.
Explosion Sensitivity to Mechanical Impact: Not sensitive.
Explosion Sensitivity to Static Discharge: Not sensitive.
Special Fire Fighting Procedures: For fires beyond the incipient stage, emergency responders in the immediate
MSDS 鈥? Moexipril HCl 7.5mg Tablets Page 3 of 6
hazard area should wear bunker gear. When the potential chemical hazard is unknown, in enclosed or confined
spaces, or when explicitly required by the DOT Emergency Response Guidebook, a self-contained breathing
apparatus should be worn. In addition, wear other appropriate protective equipment as conditions warrant (see
Section 8). Isolate immediate hazard area and keep unauthorized personnel out. Contain spill if it can be done with
minimal risk. Move undamaged containers from immediate hazard area if it can be done with minimal risk. Cool
equipment exposed to fire with water, if it can be done with minimal risk.
HAZARD CLASS: Health: 1 (Least)
Flammability: 0 (Least)
Reactivity: 0 (Least)
SECTION 6: SPILL AND LEAK PROCEDURES
Spill and Leak Response:
Clean up material and place in an appropriate disposal container. Avoid runoff into storm sewers and ditches which
lead to waterways. Consult local authorities regarding notification requirements.
SECTION 7: HANDLING AND STORAGE
Work and Hygiene Practices: As with all chemicals, avoid getting this product ON YOU or IN YOU. Do not eat,
drink, smoke or apply cosmetics while handling the product. Wash hands thoroughly after handling.
Storage and Handling Practices: Store at controlled room temperature 15掳C to 30掳C (59掳F to 86掳F) and excessive
moisture. Wash hands before eating, avoid breathing dust. Avoid contact with eyes, skin, and clothing.
Protective Practices During Maintenance of Contaminated Equipment: ND
SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION
Ventilation and Engineering Controls: No special ventilation required under normal condition of use.
Respiratory Protection: No special requirements under normal conditions, avoid breathing excessive dust.
Eye Protection: Although the risk from eye exposure is minimal, prudence recommends the use of safety glasses.
Hand Protection: No special requirements under normal condition of use.
Body Protection: No special requirements under normal conditions of use.
Product Preparation Instructions for Medical Personnel: Follow standard procedure for handling pharmaceutical
materials and recommendations presented on the Package Insert.
SECTION 9: PHYSICAL / CHEMICAL PROPERTIES
MSDS 鈥? Moexipril HCl 7.5mg Tablets Page 4 of 6
Boiling Point: ND Vapor Pressure: ND
Melting/Freezing Point: ND pH: ND
Water Solubility: Soluble Water Reactive: No
Specific Gravity (Water =1): ND Evaporation Rate (Butyl acetate = 1): ND
Appearance/Odor: Light beige, round, biconvex, film coated tablets with 鈥?110鈥? debossing on one side
and scored on the other side of the tablet. No odor.
ND = No Data
SECTION 10: STABILITY AND REACTIVITY
Stability: Stable under labeled storage conditions.
Incompatible Materials: None Known
Hazardous Polymerization: Will not occur.
Conditions to Avoid: Protect from excessive moisture. Store between 15掳C and 30掳C (59掳F to 86掳F).
SECTION 11: TOXICOLOGICAL INFORMATION
Toxicity Data: The following information is for Moexipril HCl 7.5 mg tablets.
Oral LD 50 Rat = >2000mg/kg Oral LD 50 Rat = >100000 mg/kg
(Povidone K-29) (Crospovidone XL, NF)
Suspected Cancer Agent: This product has NOT been identified as a carcinogen by NTP, IARC or OSHA.
Irritancy of Product: During normal use of product no eye contact should occur. Avoid exposure to excessive dust.
Sensitization to the Product: Not Known.
Reproductive Toxicity Information: This material is classified as a Pregnancy
Category B (Risk to Fetus Cannot be Ruled-Out). When used during the second and third trimesters of pregnancy,
ACE inhibitors, including Moexipril, can cause injury and even death to the developing fetus.
Mutagenicity: ND
Embryotoxicity/Teratogenicity/Reproductive Toxicity: ND
ACGIH Biological Exposure Indices: Currently there are no Biological Exposure Indices (BEIs) associated with the
components of this product.
SECTION 12: ECOLOGICAL INFORMATION
All work practices must be aimed at eliminating environmental contamination.
Environmental Stability: This product will be relatively stable under ambient environmental conditions.
Effect of Materials on Plants or Animals: Ecological tests results for Moexipril HCl revealed that the compound is
non-toxic to invertebrate and microbial organisms.
MSDS 鈥? Moexipril HCl 7.5mg Tablets Page 5 of 6
Effect of Chemicals on Aquatic Life: No specific information is available on the effects of Moexipril on aquatic life.
SECTION 13: WASTE DISPOSAL
Preparing Wastes for Disposal: This material, if discarded as produced, is not a RCRA 鈥渓isted鈥? or 鈥渃haracteristic鈥?
hazardous waste. Use resulting in chemical or physical change or contamination may subject it to regulation as a
hazardous waste. Along with properly characterizing all waste materials consult state and local regulations regarding
the proper disposal of this material.
U.S. EPA Waste Number: None
SECTION 14: TRANSPORTATION INFORMATION
This Material is not Hazardous as Defined by 49 CFR 172.101 by the U. S. Department of Transportation
Proper Shipping Name: Not applicable
Hazard Class Number and Description: Not applicable
UN Identification Number: Not applicable
Packing Group: Not applicable
DOT Label(s) Required: Not applicable
North American Emergency Response Guidebook Number (1996): Not applicable.
MARINE POLLUTANT: No component of this product is listed as a Marine Pollutant (49 CFR 172.101, Appendix B)
Transport Canada Transportation of Dangerous Goods Regulations: Not applicable
SECTION 15: REGULATORY INFORMATION
U.S. REGULATIONS:
U.S. SARA Reporting Requirements: 311/312 Hazard Categories: Immediate Health, 313 Reportable Ingredients:
None
U.S. SARA Threshold Planning Quantity: Not applicable
U.S. CERCLA Reportable Quantities (RQ): Not applicable
U.S. TSCA Inventory Status: Moexipril HCl is a 鈥渄rug鈥? as defined by the Federal Food, Drug and Cosmetic Act and is
therefore not a chemical substance under TSCA.
California Safe Drinking Water and Toxic Enforcement Act (Proposition 65): This product does NOT contain a
chemical known to the State of California to cause developmental and reproductive effects.
Other U.S. Federal Regulations: Based on this product鈥檚 use, the requirements of the OSHA Bloodborne pathogen
Standard (29 CFR 1910.1030) are applicable.
ANSI Labeling (Based on 129.1. Provided to Summarize Occupational Exposure Hazards):
WARNING! Moexipril HCl 7.5 mg tablets should be administered under the supervision of a qualified physician.
SECTION 16: OTHER INFORMATION
MSDS 鈥? Moexipril HCl 7.5mg Tablets Page 6 of 6
DEFINITIONS OF ABBREVATIONS USED:
ACGIH: American Conference of Governmental Industry Hygienists
CAS: Chemical Abstract Service
IARC: International Agency for Research on Cancer
IDLH: Immediately Dangerous to Life or Health Level
LC50: Medial Lethal Concentration
LD50: Medial Lethal Dose
MSHA: Mine Safety and Health Administration
N/A: Not Available
NIOSH: National Institute for Occupational Safety and Health
NTP: National Toxicology Program
OSHA: Occupational Safety and Health Administration
PEL: Permissible Exposure Limit
STEL: Short Term Exposure Limit
TLV: Threshold Limit Value
TWA: Time Weighted Average
MATERIAL SAFETY DATA SHEET
Moexipril 15 mg Tablets
Paddock Laboratories, Inc. Emergency Assistance:
CHEMTREC庐 (24-hour)
3940 Quebec Avenue North 1-800-424-9300
Minneapolis, MN 55427
Tel: (763) 546-4676 Paddock Technical Assistance: 1-800-328-5113
Creation Date: 30 August 2004 Revision Date: 30 August 2004
SECTION 1: PRODUCT IDENTIFICATION
PRODUCT NAME: Moexipril 15 mg Tablets
COMMON NAME: Moexipril 15 mg Tablets
CHEMICAL NAME: Moexipril HCl
SYNONYMS: NA
CHEMICAL FORMULA: C27H34N2O7HCl
CHEMICAL FAMILY: ACE Inhibitor, Antihypertensive
SECTION 2: COMPOSITION AND INGREDIENTS
CHEMICAL NAME CAS# % w/w OSHA PEL ACGIH TLV IDLH
Moexipril HCl 82586-52-5 <10 NE NE NE
Magnesium Oxide, USP 01309-48-4 <10 15 mg/m 3 10 mg/m 3 NE
Lactose Monohydrate, NF 64044-51-5 >50 NE NE NE
Povidone K-29 9003-39-8 <10 NE NE NE
Crospovidone XL, NF 9003-39-8 <10 NE NE NE
Colloidal Silicon Dioxide, NF 112945-52-5 <10 6 mg/m3 10 mg/m3 NE
(Aerosil 200)
Magnesium Stearate, NF 00557-04-0 <10 15 mg/m 3 10 mg/m3 NE
Opadry Mixture <10 10 mg/m3 5 mg/m 3 NE
NE = Not Established, Specific amounts are considered proprietary information.
SECTION 3: HAZARDS INDENTIFICATION
EMERGENCY OVERVIEW: Moexipril 15 mg tablets are dark beige, round, biconvex, film coated tablets with 鈥淧AD鈥?
and 鈥?112鈥? debossing on one side and scored on the other side of the tablet. The ingredients listed are non-
hazardous.
Symptoms of Overexposure by Route of Exposure: Overexposure by ingestion includes cough, diarrhea, and
flushing, rash, and muscle pain. Some individuals may experience swelling of the face, extremities, lips, tongue,
glottis, and/or larynx. Swelling of the tongue or larynx may result in difficult breathing. Overdosage results primarily
TO THE BEST OF OUR KNOWLEDGE THE INFORMATION CONTAINED HEREIN IS ACCURATE AS OF THE DATE HEREOF.
ANY DETERMINATION AS TO THE SUITABILITY OF THE PRODUCT FOR ANY PARTICULAR PURPOSE, ITS SAFE USE OR
DISPOSAL SHALL BE THE RESPONSIBILITY OF THE USER. THE INFORMATION CONTAINED HEREIN IS IN NO WAY
INTENDED TO SUPPLEMENT, MODIFY OR SUPERSEDE THE INFORMATION PROVIDED IN THE PRODUCT PACKAGE
INSERT WITH RESPECT TO THE USE OF THE PRODUCT FOR MEDICAL PURPOSES.
MSDS 鈥? Moexipril HCl 15 mg Tablets Page 2 of 6
in hypotension which could lead to dizziness, lightheadedness, and fainting.
Inhalation: Inhalation is not likely to occur, however avoid breathing or creating dust. If symptoms occur, move to
fresh air and seek medical attention.
Contact with Skin or Eyes: Contact with eyes is not likely to occur, however avoid creating dust. Incase of contact
with eyes wash thoroughly with water for at least 15 minutes and consult a physician if irritation persists. There is no
hazards associated with contact with skin, however if irritation occurs, wash thoroughly with soap and water and seek
medical attention.
Ingestion: Accidental ingestion of normal dosages (no more than 4 tablets in 24 hours for adults) is not likely of
cause significant adverse health effects.
Health Effects or Risks From Exposure (An explanation in lay terms):
Acute: Not Known
Chronic: Not Known
Medical Conditions Aggravated by Over Exposure: Congestive heart failure, ischemic heart disease (low blood
supply to the heart), aortic stenosis (narrow aortic valve which causes decreased heart function, characterized by
faint pulse in hands and feet, exercise intolerance, and/or chest pain), and cerebrovascular disease (disease of the
blood vessels of the brain.)
Other Comments: When using Moexipril during the second and third trimesters of pregnancy, ACE inhibitors can
cause injury and even death to the developing fetus.
Pre-Existing Medical Conditions: Not Known
SECTION 4: FIRST AID MEASURES
Skin Exposure: Thoroughly wash with mild soap and water if irritation develops.
Eye Exposure: Immediately flush eye with copious amounts of water and seek medical attention.
Inhalation: Inhalation exposure is not expected to occur. If symptoms occur, move to fresh air and seek
medical attention.
Ingestion: In the case of exposure to excessive levels of dust, remove to fresh air. Get medical
attention if cough or other symptoms develop.
NOTE TO PHYSICIANS: Although rare, some individuals may experience significant edema of the face, tongue,
glottis, or larynx when treated with ACE inhibitors. Appropriate treatment should be administered promptly.
SECTION 5: FIRE / EXPLOSION HAZARDS & FIRE-FIGHTING MEASURES
Flash Point: NE Autoignition Temperature: NE
Flammable Limits (in air by volume, %): Lower: NE Upper: NE
Fire Extinguishing Equipment: Use extinguishing agent suitable for type of surrounding fire.
Water Spray: OK Carbon Dioxide: OK Halon: OK
Foam: OK Dry Chemical: OK Other: Any 鈥淎BC鈥? Class
Unusual Fire and Explosion Hazards: No unusual fire or explosion hazards are expected.
Explosion Sensitivity to Mechanical Impact: Not sensitive.
Explosion Sensitivity to Static Discharge: Not sensitive.
MSDS 鈥? Moexipril HCl 15 mg Tablets Page 3 of 6
Special Fire Fighting Procedures: For fires beyond the incipient stage, emergency responders in the immediate
hazard area should wear bunker gear. When the potential chemical hazard is unknown, in enclosed or confined
spaces, or when explicitly required by the DOT Emergency Response Guidebook, a self-contained breathing
apparatus should be worn. In addition, wear other appropriate protective equipment as conditions warrant (see
Section 8). Isolate immediate hazard area and keep unauthorized personnel out. Contain spill if it can be done with
minimal risk. Move undamaged containers from immediate hazard area if it can be done with minimal risk. Cool
equipment exposed to fire with water, if it can be done with minimal risk.
HAZARD CLASS: Health: 1 (Least)
Flammability: 0 (Least)
Reactivity: 0 (Least)
SECTION 6: SPILL AND LEAK PROCEDURES
Spill and Leak Response:
Clean up material and place in an appropriate disposal container. Avoid runoff into storm sewers and ditches which
lead to waterways. Consult local authorities regarding notification requirements.
SECTION 7: HANDLING AND STORAGE
Work and Hygiene Practices: As with all chemicals, avoid getting this product ON YOU or IN YOU. Do not eat,
drink, smoke or apply cosmetics while handling the product. Wash hands thoroughly after handling.
Storage and Handling Practices: Store at controlled room temperature 15掳C to 30掳C (59掳F to 86掳F) and excessive
moisture. Wash hands before eating, avoid breathing dust. Avoid contact with eyes, skin, and clothing.
Protective Practices During Maintenance of Contaminated Equipment: ND
SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION
Ventilation and Engineering Controls: No special ventilation required under normal condition of use.
Respiratory Protection: No special requirements under normal conditions, avoid breathing excessive dust.
Eye Protection: Although the risk from eye exposure is minimal, prudence recommends the use of safety glasses.
Hand Protection: No special requirements under normal condition of use.
Body Protection: No special requirements under normal conditions of use.
Product Preparation Instructions for Medical Personnel: Follow standard procedure for handling pharmaceutical
materials and recommendations presented on the Package Insert.
MSDS 鈥? Moexipril HCl 15 mg Tablets Page 4 of 6
SECTION 9: PHYSICAL / CHEMICAL PROPERTIES
Boiling Point: ND Vapor Pressure: ND
Melting/Freezing Point: ND pH: ND
Water Solubility: Soluble Water Reactive: No
Specific Gravity (Water =1): ND Evaporation Rate (Butyl acetate = 1): ND
Appearance/Odor: Dark beige, round, biconvex, film coated tablet, with 鈥淧AD鈥? and 鈥?112鈥? debossing on
one side and scored on the other side of the tablet.
ND = No Data
SECTION 10: STABILITY AND REACTIVITY
Stability: Stable under labeled storage conditions.
Incompatible Materials: None Known
Hazardous Polymerization: Will not occur.
Conditions to Avoid: Protect from excessive moisture. Store between 15掳C and 30掳C (59掳F to 86掳F).
SECTION 11: TOXICOLOGICAL INFORMATION
Toxicity Data: The following information is for Moexipril HCl 15 mg tablets.
Oral LD 50 Rat = >2000mg/kg Oral LD 50 Rat = >100000 mg/kg
(Povidone K-29) (Crospovidone XL, NF)
Suspected Cancer Agent: This product has NOT been identified as a carcinogen by NTP, IARC or OSHA.
Irritancy of Product: During normal use of product no eye contact should occur. Avoid exposure to excessive dust.
Sensitization to the Product: Not Known.
Reproductive Toxicity Information: This material is classified as a Pregnancy
Category B (Risk to Fetus Cannot be Ruled-Out). When used during the second and third trimesters of pregnancy,
ACE inhibitors, including Moexipril, can cause injury and even death to the developing fetus.
Mutagenicity: ND
Embryotoxicity/Teratogenicity/Reproductive Toxicity: ND
ACGIH Biological Exposure Indices: Currently there are no Biological Exposure Indices (BEIs) associated with the
components of this product.
SECTION 12: ECOLOGICAL INFORMATION
All work practices must be aimed at eliminating environmental contamination.
Environmental Stability: This product will be relatively stable under ambient environmental conditions.
Effect of Materials on Plants or Animals: Ecological tests results for Moexipril HCl revealed that the compound is
MSDS 鈥? Moexipril HCl 15 mg Tablets Page 5 of 6
non-toxic to invertebrate and microbial organisms.
Effect of Chemicals on Aquatic Life: No specific information is available on the effects of Moexipril on aquatic life.
SECTION 13: WASTE DISPOSAL
Preparing Wastes for Disposal: This material, if discarded as produced, is not a RCRA 鈥渓isted鈥? or 鈥渃haracteristic鈥?
hazardous waste. Use resulting in chemical or physical change or contamination may subject it to regulation as a
hazardous waste. Along with properly characterizing all waste materials consult state and local regulations regarding
the proper disposal of this material.
U.S. EPA Waste Number: None
SECTION 14: TRANSPORTATION INFORMATION
This Material is not Hazardous as Defined by 49 CFR 172.101 by the U. S. Department of Transportation
Proper Shipping Name: Not applicable
Hazard Class Number and Description: Not applicable
UN Identification Number: Not applicable
Packing Group: Not applicable
DOT Label(s) Required: Not applicable
North American Emergency Response Guidebook Number (1996): Not applicable.
MARINE POLLUTANT: No component of this product is listed as a Marine Pollutant (49 CFR 172.101, Appendix B)
Transport Canada Transportation of Dangerous Goods Regulations: Not applicable
SECTION 15: REGULATORY INFORMATION
U.S. REGULATIONS:
U.S. SARA Reporting Requirements: 311/312 Hazard Categories: Immediate Health, 313 Reportable Ingredients:
None
U.S. SARA Threshold Planning Quantity: Not applicable
U.S. CERCLA Reportable Quantities (RQ): Not applicable
U.S. TSCA Inventory Status: Moexipril HCl is a 鈥渄rug鈥? as defined by the Federal Food, Drug and Cosmetic Act and is
therefore not a chemical substance under TSCA.
California Safe Drinking Water and Toxic Enforcement Act (Proposition 65): This product does NOT contain a
chemical known to the State of California to cause developmental and reproductive effects.
Other U.S. Federal Regulations: Based on this product鈥檚 use, the requirements of the OSHA Bloodborne pathogen
Standard (29 CFR 1910.1030) are applicable.
ANSI Labeling (Based on 129.1. Provided to Summarize Occupational Exposure Hazards):
WARNING! Moexipril HCl 15 mg tablets should be administered under the supervision of a qualified physician.
MSDS 鈥? Moexipril HCl 15 mg Tablets Page 6 of 6
SECTION 16: OTHER INFORMATION
DEFINITIONS OF ABBREVATIONS USED:
ACGIH: American Conference of Governmental Industry Hygienists
CAS: Chemical Abstract Service
IARC: International Agency for Research on Cancer
IDLH: Immediately Dangerous to Life or Health Level
LC50: Medial Lethal Concentration
LD50: Medial Lethal Dose
MSHA: Mine Safety and Health Administration
N/A: Not Available
NIOSH: National Institute for Occupational Safety and Health
NTP: National Toxicology Program
OSHA: Occupational Safety and Health Administration
PEL: Permissible Exposure Limit
STEL: Short Term Exposure Limit
TLV: Threshold Limit Value
TWA: Time Weighted Average
|